The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...
Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...
Roche’s diagnostics business continues to be buffeted by China headwinds, but the Swiss major believes it has enough ...
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...
Parikh is backed up by experienced CRO leader William Gannon Jr., M.D., who is LyfeSci’s chief medical officer. Gannon has ...
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions that the Japanese business took earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback